About 15% to 20% of all clinically recognized pregnancies result in spontaneous abortion or miscarriage, and chromosomal anomalies can be identified in up to 50% of first trimester miscarriages. Chromosomal microarray analysis (CMA) is currently considered first-tier testing for detecting fetal chromosomal abnormalities and is supported by the absence of cell culture failure or erroneous results due to cell contamination in pregnancy loss. Triploidy is a lethal chromosome number abnormality characterized by an extra haploid set of chromosomes. Triploidy is one of the most common chromosomal aberrations in first trimester spontaneous abortions. Here, we report two cases of triploidy abortion that were not detected using array comparative genomic hybridization-based CMA. The aim of this report was to remind clinicians of the limitations of chromosomal testing and the misdiagnosis that can result from biased test selection.
Introduction
An estimated 15% to 20% of clinically recognized pregnancies end in miscarriage (loss of pregnancy less than 20 weeks gestation) [1] . The single most common cause of early pregnancy loss is the presence of a fetal chromosomal abnormality, which is responsible for more than 50% of losses in the first trimester [2] . The diagnosis of chromosomal abnormalities in pregnancy loss is essential to establish the etiology of fetal losses and to assess patients with risks of recurrence. Such a diagnosis can also relieve feelings of guilt associated with pregnancy loss and provide options for prenatal or preimplantation genetic testing in future pregnancies [3] .
Triploidy is a chromosomal aberration caused by the presence of an extra haploid chromosome set. Triploidy is the second most frequent chromosomal abnormality in early pregnancy loss with chromosomal abnormalities, following trisomy, and is responsible for about 13% of these losses [3] .
Recent studies have provided support for the utility of chromosomal microarray analysis (CMA) testing in pregnancy loss [4, 5] . The main reasons are the elimination of cell culture failures, the risk of erroneous results due to maternal cell contamination, and the delay of as much as 2 weeks in obtaining conventional karyotyping results. Therefore, the CMA method is increasingly considered the robust choice for the genetic analysis of pregnancy loss. However, CMA also has limitations. Because CMA only identifies the differences reflected by the patient's imbalance compared with the control, a balanced rearrangement is not detected. Specifically, comparative genomic hybridization (CGH)-based arrays cannot detect triploidy. Here, we report two cases of triploidy abortion that were not identifiable using array CGH-based CMA.
Case 1. Case 1
A 37-year-old nulliparous woman was referred for a small gestational sac relative to the expected gestational week (9+5 weeks of gestation). She became pregnant by natural ovulation and coitus. Four previous in vitro fertilization-embryo transfers were performed before this natural pregnancy, and all resulted in implantation failure. She denied using teratogenic medications, recent viral infection, diabetes mellitus, or hypertension. She and her husband were non-consanguineous and appeared healthy. There was no family history of congenital malformation. Her husband was 39 years of age. Ultrasonography (USG) showed a 7+5-week-sized gestational sac (27 mm), 9+1-weeksized embryo (24 mm), but no heartbeat ( Fig. 1A) . We decided to perform dilatation and evacuation (D&E) under the diagnosis of early pregnancy loss. In addition, aborted tissue and parental chromosome tests were planned for future pregnancies. D&E was performed with adjuvant prostaglandin E1 at 10+3 weeks of gestation. Conventional parental karyotyping was performed. The villi of the abortions were genetically tested using two methods: CMA and conventional karyotyping. Both parents had normal chromosome complements in peripheral blood lymphocytes. In the villi of the aborted tissues analyzed by array CGH (CancerROP, Seoul, Korea), no chromosome alterations were found ( Fig. 2A ), but conventional karyotyping confirmed triploidy (69, XXX) ( Fig. 3A ).
Case 2
A 33-year-old nulliparous woman was referred for a small gestational sac relative to the expected gestational week (7+2 weeks of gestation). She became pregnant by natural ovulation and coitus. She denied using teratogenic medications, recent viral infection, diabetes mellitus, or hypertension. She and her husband were non-consanguineous and appeared healthy. There was no family history of congenital malformation. Her husband was 35 years of age. The first USG showed a 5+6-weeksized gestational sac (10.5 mm), 7+1-week-sized embryo (11 mm) ( Fig. 1B) , and a heartbeat was observed. After 10 days, she visited the hospital with vaginal spotting. No fetal heartbeat was observed on the second USG, with a 6+2-week-sized gestational sac (15.3 mm) and 7+0-week-sized embryo (9.7 mm). D&E was performed under a diagnosis of early pregnancy loss. In addition, aborted tissue chromosome tests were planned for future pregnancies. The D&E was performed with adjuvant prostaglandin E1 at 8+5 weeks of gestation. The aborted tissue was karyotyped using CMA and conventional karyotyping. In the villi of aborted tissue analyzed by array-CGH, no chromosome alterations were found (Fig. 2B ), but conventional karyotyping confirmed triploidy (69, XXX) ( Fig. 3B) .
In both cases, villus samples were collected from the aborted tissue. The samples were obtained by D&E after spontaneous abortion and collected in sterile containers containing 10 mL of F-10 (1×) with l-glutamine (Invitrogen, Carlsbad, CA, USA). The villi chromosomes were tested using the following two techniques.
Cytogenetic analysis
In the genetics laboratory, trained technologists dissected and selected the placental chorionic villi and cultured them in Chang Medium C (Irvine Scientific, Santa Ana, CA, USA) at 37°C in a 5% CO 2 incubator. Whenever the material contained chorionic villi, both short-and long-term cultures were set up. All procedures, including cell harvesting, slide preparation, and staining, were conducted following standard protocols. The chromosomes were analyzed after G-banding using Wright stain. At least 20 GTG-banded metaphases were examined and the final assess-ment was made by the cytogenetics laboratory director.
Array CGH
The array CGH slides (CancerROP) were analyzed using the ChromoFluor image analysis system (Array Analysis; Cancer-ROP). The slides contained 1,440 human bacterial artificial chromosome (BAC) clones including the specific loci of more than 200 chromosomal disorders and 356 cancer-related genes from BAC libraries at an average resolution of 0.1 to 2.3 Mb for the entire genome. Each BAC clone was represented on the array with three spots, and each array was scanned using a GenePix 4000B scanner (Axon Instruments, Foster City, CA, USA) and analyzed with Array Analysis (CancerROP). Normal Korean pooled genomic DNA was used as reference DNA (CancerROP). The green (test) to red (reference) (G/R) ratios were determined automatically for each sample, and the normalized G/R ratio represented the relative average number of copies of the sequence for those spots that were selected as controls. Spots with G/R ratios of the mean plus 0.25 standard deviations or more (i.e., G/R ≥1.25) were considered to show amplification or gain of the indicated copy number, whereas those with G/R ratios of the mean minus 0.25 standard deviations or less (i.e., G/R ≤0.75) were considered to show a loss of copy number.
Discussion
CMA is a high-resolution technique for measuring the gain and loss of DNA throughout the human genome. CMA provides higher resolution than conventional karyotyping, which enables the detection of sub-microscopic deletions and duplications of 50 to 100 kb [6] . Based on this, the American College of Obstetricians and Gynecologists (ACOG) and Society for Maternal and Fetal Medicine (SMFM) published a statement recommending CMA as the first-line test when prenatal USG shows major fetal abnormalities or fetal demise [7] . This was reinforced by updated ACOG and SMFM practice bulletins, and when fetal structural abnormalities are discovered by USG, CMA should be conducted with the primary test replacing karyotyping [8] .
There are two major platforms for CMA: CGH and single nucleotide polymorphism (SNP) arrays. CGH array enables detection of the gain and loss of genomic regions through hybridization of different colored fluorescent-labeled fetal and reference DNA samples. Genomic imbalances can be identified by measuring the signal intensity ratio between the fetal and reference DNA on individual targets and their genomic location after a normalization process. Target DNA fragments aligned on a microarray are called probes, and the resolution of the microarray is determined by the type and number of probes and their distribution on the genome. A typical clinical CGH array contains a few hundred thousand probes, whereas the number of probes on research CGH arrays may reach into the millions [9] . As the intensity of resulting data is typically plotted as a Log2 ratio, where a log2 ratio of zero represents a normal DNA copy number of 2, triploidy cannot be detected by CGH array because the Log2 ratios for a normal diploid sample and a triploid sample are indistinguishable [10] . SNP arrays were originally designed to detect common SNPs and are mainly used for genotyping individuals in genome-wide association studies of multifactorial diseases. However, such platforms can also be used to analyze copy-number variants (CNVs) to compare signal intensities of fetal and reference targets as used in the CGH approach [11, 12] . SNP arrays can detect triploidy as well as CNVs by assessing the SNP allele patterns on the array, but CGH arrays cannot detect triploidy [9] . In addition, the existing commercial SNP chip is Western-oriented, and has a low genome representation of Asians [13] .
Triploidy is one of the most common chromosomal abnormalities; it occurs in 1% to 2% of all conceptuses and accounts for more than 10% of all spontaneous abortions [14] . The primary mechanisms leading to triploidy include dispermy and maternal (digynic triploidy) or paternal (diandric triploidy) meiotic errors [15] . Unlike most chromosomal abnormalities, increased maternal age is not a risk factor for digynic or diandric triploidy. However, there have been several reports of recurrent (≥3 times) triploidy [16] [17] [18] , and one study examined possible genetic vari-ants responsible for this phenotype [19] . These reports support the need for chromosome diagnosis in early pregnancy loss.
In the analysis of early pregnancy loss, the CGH array is limited in that it cannot reliably detect triploidy, which accounts for 10% of all early pregnancy loss; thus, applying CMA uniformly, without knowledge of each platform, is not a reasonable approach for identifying chromosomal abnormalities in early pregnancy loss. Therefore, before choosing a chromosome test, CMA sub-methods should be given careful consideration, and conventional karyotyping is still important when options are limited. Moreover, because CMA finds genomic imbalances, this technique cannot detect balanced chromosomal rearrangements. In addition, CMA does not provide information about the chromosomal mechanisms of genetic imbalance [20] ; for example, if there is a gain of a particular chromosome, CMA cannot distinguish between trisomy and unbalanced Robertsonian translocations, thus there are limitations regarding counseling related to the risk of recurrence. Therefore, excluding conventional karyotyping can have unintended negative consequences.
We report two cases of triploidy that escaped diagnosis using CGH array-based CMA. As mentioned above, because CMA has several platforms and each has advantages and disadvantages, it is important to understand the characteristics and limitations of each platform when selecting a microarray. Thus, in prenatal chromosome testing, particularly in early pregnancy failure, conventional karyotyping is still important and valid in clinical practice. We suggest that providers choose a method based on individual availability and consideration of the strengths and limitations of each test as it applies to each clinical scenario.
